



The Relationship between Risk Factors for Metabolic Syndrome and Bone Mineral Density in Menopausal Korean Women

*Seok-Hee KIM¹, *Jooyoung KIM²*

1. *School of Humanities and Social Science, College of Liberal Arts and Convergence Sciences, Korea Advanced Institute of Science and Technology, Daejeon-si, Republic of Korea*

2. *Department of Anatomy, School of Medicine, Kyungpook National University, Daegu-si, Korea*

***Corresponding Author:** Email: hirase1125@hanmail.net

(Received 16 Sep 2018; accepted 22 Nov 2018)

Abstract

Background: The risk factors of metabolic syndrome (MetS) in menopausal women are potential causes of osteoporosis. However, there is no consensus on this. We aimed to determine the relationship between risk factors of MetS and bone mineral density (BMD) in menopausal Korean women.

Methods: We enrolled 205 menopausal Korean women who visited a health promotion center in Seoul in 2015 and divided them into the following two groups according to the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria with modified waist-circumference criteria: the non-MetS group (Group 1, n=90) and the MetS group (Group 2, n=115). Anthropometric parameters and clinical parameters, including blood pressure, blood lipid profile (cholesterol, triglycerides), and fasting blood sugar levels were recorded for all participants. BMD at the lumbar spine was determined using dual-energy X-ray absorptiometry (DEXA). The relationship between the risk factors of MetS and bone mineral density was analyzed by statistical methods.

Results: There was no significant difference in risk factors of MetS between the groups. In correlation tests, waist circumference showed a significant association with body surface area (BSA) ($r = -0.242, P < 0.001$). Diastolic blood pressure was correlated with BSA ($r = 0.186, P < 0.01$) and bone mineral content (BMC) ($r = 0.161, P < 0.05$). However, multiple regression analysis showed no significant relationship between MetS risk factors and BMD.

Conclusion: The risk factors of MetS did not affect BMD in menopausal Korean women. Follow-up studies with a larger study population are necessary size to allow the investigation of other research variables.

Keywords: Bone mineral density; Menopausal women; Metabolic syndrome; Osteoporosis; Korea

Introduction

Metabolic syndrome (MetS) is a disorder characterized by abdominal obesity, hyperglycemia, hypertension, and dyslipidemia. It is known to be significantly associated with increased risk of cardiovascular disease and resulting death (1). MetS increases with age, and its prevalence is especially high in menopausal women (2). Estrogen

deficiency in menopausal women causes abdominal adipose-tissue accumulation and inflammation, decreases in vascular elasticity and endothelial cell function and increased low-density lipoprotein cholesterol (LDL-C) (3).

Another health problem that may appear in menopausal women is osteoporosis (4). The primary

cause of osteoporosis in menopausal women is estrogen deficiency (5). The decrease in estrogen secretion impairs the normal bone turnover cycle, increasing osteoclastic resorption activity while reducing osteoblastic activity (6). As a result, bone loss increases, and the risk of osteoporosis increases. This change is a major cause of reduced quality of life due to increased susceptibility to fractures and is a major threat to health in menopausal women (7).

MetS in menopausal women may promote bone mineral density (BMD) reduction (8-10). The reduction of high-density lipoprotein cholesterol (HDL-C) suppresses osteogenic activity in vascular cells, and abdominal obesity increases inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- α) (10). Increased blood pressure damages calcium homeostasis, partly due to urinary calcium excretion (11). Increased triglycerides reduce hypercalciuria and insulin-like growth factor-1 (IGF-1) and blood flow to the bone, leading to decreased BMD (10,12).

However, there was no correlation between MetS and decreased BMD in menopausal women (13-16). However, menopausal women with MetS had a higher T-scores of the femoral neck than those without MetS (17), and BMD was higher in menopausal women with lower HDL-C levels (18). In addition, obesity and overweight have been separately reported to have a protective effect on bone loss and thereby reduce the fracture risk (19-21).

Thus, research has shown inconsistent results regarding the relationship between MetS and BMD in menopausal women, and the correlation and causation are still unclear. Nevertheless, considering a report of low BMD in Asian women compared to Caucasians (22) and recent studies (10, 23) that continue to highlight the health problems of menopausal women, especially a decrease in BMD by MetS, it is necessary to make continuous attempts to elucidate the relationship between the two variables. Moreover, while Korea has focused on treatment for menopausal women with osteoporosis, its efforts at prevention by identifying and reducing potential risk

factors have been relatively limited (24-25).

Therefore, we aimed to investigate the relationship between BMD and the risk factors of MetS in menopausal Korean women and to provide basic data on BMD decrease and its prevention.

Materials and Methods

Subjects

Subjects were 205 menopausal women who visited a health promotion center in Seoul in 2015 and received an examination. Menopause was defined as cessation of menstruation for at least one year. The researchers fully explained the purpose and contents of the study to all study subjects. Then, the subjects voluntarily agreed to participate in the study and signed an informed consent form. Those who were receiving medication or hormone replacement therapy for osteoporosis treatment or had a history of thyroid dysfunction or rheumatoid arthritis were excluded from this study.

The study subjects were divided by diagnosis into a non-MetS group (Group 1, n = 90) and a MetS group (Group 2, n = 115). MetS was diagnosed when three or more risk factors, including blood pressure, blood glucose, triglycerides, HDL-C, and abdominal obesity met specific thresholds. Except for the waist-circumference criterion used to diagnose abdominal obesity, other risk factors of MetS were based on the criteria presented in the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) (26).

The criteria presented by the NCEP-ATP III are as follows: 1) systolic blood pressure (SBP) \geq 130 mmHg or diastolic blood pressure (DBP) \geq 85 mmHg; 2) fasting blood sugar \geq 100 mg/dl; 3) triglycerides \geq 150 mg/dl; and 4) high density lipoprotein cholesterol (HDL-C) \leq 50 mg/dl. The waist-circumference criterion was modified to take into account the sex and race of the subjects, and was set to be 80 cm or more as suggested by the World Health Organization, West Pacific Region, in 2000 (27). The characteristics of the study subjects in each group are shown in Table 1.

Table 1: Differences in BMD-related factors according to the diagnosis of the metabolic syndrome

<i>Item</i>	<i>Group 1 (n=90)</i>	<i>Group 2 (n=115)</i>	<i>t</i>
Age (yr)	63.19±3.27	64.36±3.34	-2.502*
Height (cm)	153.91±4.69	153.96±4.95	-.079
Body weight (kg)	56.55±7.14	59.19±6.44	-2.771**
BMI (kg/m ²)	23.86±2.69	24.97±2.54	-3.019**
WC (cm)	81.62±0.40	83.23±0.38	-2.892**
SBP (mmHg)	119.73±9.75	136.80±14.78	-9.926***
DBP (mmHg)	72.04±8.05	81.43±10.00	-7.253***
TG (mg/dl)	93.34±28.39	155.53±71.68	-7.764***
HDL-C (mg/dl)	62.42±9.38	61.79±10.43	0.449
FBS (mg/dl)	84.53±16.58	89.33±17.03	-2.027*

Values are Mean±standard deviation, Group 1: non-metabolic-syndrome group, Group 2: metabolic-syndrome group, t; result of independent t-test, BMI; body mass index, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic blood pressure, TG; triglyceride, HDL-C; high density lipoprotein cholesterol, FBS; fasting blood sugar. **P*<0.05, ***P*<0.01, ****P*<.001

Data collection

Height and weight were measured using an automatic anthropometer (GL-150, G-Tech International Co., Ltd., Uijeongbu, Korea), and the body mass index was calculated as body weight (kg)/height (m²). The waist circumference was measured at the midpoint between the lowest rib and the upper iliac crest using a tape measure on exhalation. Blood pressure was measured using an automatic blood pressure monitor (EASY X800 R/L, Jawon Medical Co., Ltd., Gyeongsan, Korea) after resting for 5 minutes in a sitting position before measurement, and the mean value was recorded after two measurements at a 3-min interval. To obtain blood samples for the measurement of fasting blood sugar, high density lipoprotein cholesterol, and triglycerides, blood was collected from a forearm vein between 8 am and 10 am, after an 8-hour fast. All blood samples were analyzed using an Auto Biochemistry Analyzer (Express 550 Plus, Bayer, New Jersey, USA). A dual-energy X-ray absorptiometry (DEXA) unit (Discovery, Hologic Inc, CA, USA) was used for BMD measurements. BMD was measured at the lumbar spine (L1–L4) in a supine position. Total bone mineral content (BMC) values for each area from L1–L4 were presented as grams of bone per cm², and the T-score (comparison

between subjects and young normal adults) and Z-score (comparison with subject's age/sex group) were calculated. The difference between the subject and the normal group was divided by the standard deviation. The T-score was thus calculated as (subject BMD – mean young BMD)/1SD. The value was defined as: normal when > -1.00; osteopenia, -1.00 to -2.49; and, osteoporosis, ≤ -2.50, according to the World Health Organization criteria (28). The Z-score formula was (subject BMD – mean BMD for same age group)/1SD, and calculated values of less than -2.00 required additional examination to investigate a diagnosis of metabolic bone disease (29).

Statistical analysis

All data in this study are presented as mean (standard deviation). Independent *t*-test was performed to compare the mean difference between the two groups according to the diagnosis of MetS. Pearson correlation was used to analyze the relationship between risk factors of MetS and BMD. Multiple regression analysis was performed to examine the effect of risk factors of MetS on BMD. All data were analyzed using statistical analysis software (SPSS ver. 18.0, IBM Corp., Armonk, NY, USA). Statistical significance

was set at $P < 0.05$.

Results

Table 2 shows the differences in BMD-related factors between the groups. There was no significant difference in BMD-related factors between the MetS and non-MetS groups. The levels of T-scores in this study reflected osteopenia, rather

than osteoporosis. Table 3 shows the results of the correlation between risk factors of MetS and BMD. In terms of the relationship between risk factors of MetS and BMD factors, a significantly negative correlation was observed between body surface area (BSA) and waist circumference ($r = -0.242$, $P < 0.001$). Diastolic blood pressure showed a positive correlation with BSA ($r = 0.186$, $P < 0.01$) and BMC ($r = 0.161$, $P < 0.05$).

Table 2: Differences in BMD signs grouped by diagnosis of metabolic syndrome

Variable	Group 1 (n=90)	Group 2 (n=115)	t
BSA (cm ²)	53.69±4.45	53.98±4.59	-0.445
BMC (g)	43.78±8.55	45.11±9.71	-1.041
BMD (g/m ²)	0.81±0.12	0.82±0.13	-1.004
T-score	-1.68±1.05	-1.53±1.17	-0.965
Z-score	0.22±0.82	0.40±0.92	-1.452

Tested by independent t-test. Values are Mean±standard deviation.
Group 1: non-metabolic-syndrome group, Group 2: metabolic-syndrome group, BSA; body surface area, BMC; bone mineral content, BMD; bone mineral density

Table 3: Correlation between risk factors of metabolic syndrome and BMD-related factors

Variable	BSA	BMC	BMD	T-score	Z-score
WC	-0.242***	-0.113	-0.015	-0.024	0.011
SBP	0.132	0.112	0.072	0.071	0.101
DBP	0.186**	0.161*	0.111	0.109	0.129
TG	-0.061	0.019	0.047	0.048	0.057
HDL-C	0.007	-0.050	-0.071	-0.070	-0.074
FBS	0.104	0.077	0.049	0.045	0.063

All values but T and Z scores are t values from Pearson correlation test, BSA; body surface area, BMC; bone mineral content, BMD; bone mineral density, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic blood pressure, TG; triglyceride, HDL-C; high density lipoprotein cholesterol FBS; fasting blood sugar, * $P < .05$ ** $P < .01$ *** $P < .001$

The results of multiple regression analysis conducted to investigate the effect of risk factors of MetS on BMD are shown in Tables 4 and 5. When the T-score change was 24.0% and the F value was 0.600, none of the MetS risk factors showed a significant regression coefficient. In addition, when the Z-score change was 2.9% and the F-value was 0.733, a significant regression coefficient was not observed for any MetS risk factor.

Discussion

This study aimed to investigate the relationship between BMD and risk factors of MetS in menopausal Korean women. The study results show that there was no statistically significant difference in BMD-related factors between the MetS and non-MetS groups. Pearson's correlation analysis showed that there was a significant negative correlation between waist circumference and BSA of menopausal Korean women. Diastolic

blood pressure was also positively correlated with BSA and BMC. However, multiple regression analysis did not reveal a significant relationship between BMD and risk factors of MetS. These

results suggest that the risk factors of MetS in menopausal Korean women have no significant effect on BMD.

Table 4: Multiple regression analysis of the effects of risk factors of metabolic-syndrome on T-score

<i>Variable</i>	<i>B</i>	<i>SE</i>	β	<i>t</i>	<i>P</i>
MetS	0.060	0.219	0.027	0.274	0.784
WC	-1.450	2.080	-0.052	-0.697	0.487
SBP	-0.005	0.010	-0.066	-0.462	0.645
DBP	0.018	0.014	0.165	1.249	0.213
TG	0.000	0.001	0.012	0.141	0.888
HDL-C	-0.009	0.010	-0.080	-0.918	0.360
FBS	0.002	0.005	0.031	0.420	0.675

B; unstandardized beta, SE; standard error, β ; standardized beta, MetS; metabolic syndrome, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic blood pressure, TG; triglyceride, HDL-C; high density lipoprotein cholesterol, FBS; fasting blood sugar

Table 5: Multiple regression analysis of the effects of the risk factors of metabolic-syndrome on Z-score

<i>Variable</i>	<i>B</i>	<i>SE</i>	β	<i>t</i>	<i>P</i>
MetS	0.090	0.173	0.051	0.521	0.603
WC	-0.576	1.641	-0.026	-0.351	0.726
SBP	-0.002	0.008	-0.042	-0.295	0.768
DBP	0.013	0.011	0.148	1.118	0.265
TG	2.709	0.001	0.002	0.023	0.981
HDL-C	-0.008	0.008	-0.089	-1.033	0.303
FBS	0.002	0.004	0.044	0.600	0.549

B; unstandardized beta, SE; standard error, β ; standardized beta, MetS; metabolic syndrome, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic blood pressure, TG; triglycerides, HDL-C; high density lipoprotein cholesterol, FBS; fasting blood sugar

The results of this study are similar to those of several previous studies (13, 20). There was no significant difference in lumbar or femoral neck densities between women with and without MetS in studies involving menopausal Iranian women (13). A study on menopausal Moroccan women revealed no difference in the incidence of vertebral fracture between women diagnosed with MetS and those who were not (20).

However, contrary to the present study, several studies have reported that MetS in postmenopausal women reduces BMD (4,9). In addition, because BMD reduction has similar pathogenesis with arteriosclerosis, cardiovascular disease risk factors in menopausal women are associated with

osteoporosis (30-31). In addition, the BMD of menopausal women with MetS was higher (32). This may have been because post-menopausal estrogen deficiency accompanies abdominal obesity and weight gain, resulting in an increase in the physical load on the bone and mitigating any decrease in BMD due to MetS (33).

Potential causes of such differences in outcomes among the studies include either the characteristics of the study subject groups, or genetic factors. A comparison of studies between those reporting relevant effects versus no relevance for MetS on BMD indicates that the studies involved different races or nationalities (4,17,32). For example, some works involved menopausal Turkish

women (17, 23), and post-menopausal Tibetan women (4). Some studies have reported differences in bone health and bone density-related disease among races and countries (34), which have been confirmed by studies presenting the prevalence of osteoporosis in menopausal women in each country (35-36). For example, the prevalence of osteoporosis in the hip joint and lumbar spine of menopausal Moroccan women was 6.7% and 37.9%, respectively (35), and that of menopausal Saudi Arabian women was 44.1% and 46.7%, respectively (36).

This study had some limitations. First, since this study used a cross-sectional design, the effect of MetS on BMD in menopausal women over time could not be identified, and no clear causal relationship between the two variables could be determined. Second, this study involved only menopausal women living in Seoul, Korea. Therefore, it is difficult to generalize the findings to all menopausal women. Third, because the ages of the study subjects were limited to those in their 60s, results for older post-menopausal women were not analyzed. Fourth, bone-metabolism-related factors such as vitamin D, blood levels of calcium and osteocalcin, inflammatory factors, physical activity, exercise, eating behavior, smoking, alcohol consumption, and exposure to sunlight, all of which may affect BMD of menopausal women, were not investigated or measured in this study, which may confound the interpretation of the results of this study. Lastly, because BMD was measured only in the lumbar spine, the relationship between MetS and BMD at the femur in menopausal women was not confirmed.

Conclusion

The risk factors of MetS in menopausal Korean women have no significant effect on BMD. Therefore, the role of risk factors of MetS in predicting BMD changes in menopausal Korean women seems to be limited. In follow-up studies, it is necessary to increase the size of the group and investigate other research variables

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Conflict of interest

The authors declare that there are no conflicts of interests.

References

1. Kachur S, Morera R, De Schutter A, et al (2018). Cardiovascular risk in patients with prehypertension and the metabolic syndrome. *Curr Hypertens Rep*, 20(2):15.
2. Iglseider B, Cip P, Malaimare L, et al (2005). The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. *Stroke*, 36:1212-1217.
3. Carr MC, Kim KH, Zambon A, et al (2000). Changes in LDL density across the menopausal transition. *J Investig Med*, 48:245-250.
4. Zhou L, Song J, Yang S, et al (2017). Bone mass loss is associated with systolic blood pressure in postmenopausal women with type 2 diabetes in Tibet: a retrospective cross-sectional study. *Osteoporos Int*, 28:1693-1698.
5. Lerner UH (2006). Bone remodeling in postmenopausal osteoporosis. *J Dent Res*, 85:584-595.
6. Ji MX, Yu Q (2015). Primary osteoporosis in postmenopausal women. *Chronic Dis Transl Med*, 1:9-13.
7. Gambacciani M, Vacca F (2004). Postmenopausal osteoporosis and hormone replacement therapy. *Minerva Med*, 95:507-520.
8. Kim KC, Shin DH, Lee SY, et al (2010). Relation between obesity and bone mineral density and vertebral fractures in Korean postmenopausal women. *Yonsei Med J*, 51:857-863.
9. Wong SK, Chin KY, Suhaimi FH, et al (2016). The relationship between metabolic

- syndrome and osteoporosis: a review. *Nutrients*, 8(6):pii:E347.
10. da Silva VN, Fiorelli LN, da Silva CC, et al (2017). Do metabolic syndrome and its components have an impact on bone mineral density in adolescents? *Nutr Metab (Lond)*, 14:1.
 11. McFarlane SI (2006). Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights. *J Cardiometab Syndr*, 1:53-57.
 12. Bredella MA, Gill CM, Gerweck AV, et al (2013). Ectopic and serum lipid levels are positively associated with bone marrow fat in obesity. *Radiology*, 269:534-541.
 13. Abbasi M, Farzam SA, Mamaghani Z, et al (2017). Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women. *Diabetes Metab Syndr*, 11(Suppl 1):S73-S76.
 14. Caglayan EK, Engin-Ustun Y, Sari N, et al (2015). Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. *J Menopausal Med*, 21:36-40.
 15. Indhavivadhana S, Rattanasrithong P (2015). The relationship between bone mineral density and metabolic syndrome in peri- and postmenopausal Thai women. *Arch Gynecol Obstet*, 292:1127-1133.
 16. Zanatta LCB, Boguszewski CL, Borba VZ, et al (2018). Association between undercarboxylated osteocalcin, bone mineral density, and metabolic parameters in postmenopausal women. *Arch Endocrinol Metab*, 62:446-451.
 17. Ozelci R, Dilbaz B, Ozkaya E, et al (2016). Association between bone mineral density and metabolic syndrome in Turkish women who were postmenopausal. *Int J Gynaecol Obstet*, 133:370-374.
 18. Park KK, Kim SJ, Moon ES (2010). Association between bone mineral density and metabolic syndrome in postmenopausal Korean women. *Gynecol Obstet Invest*, 69:145-152.
 19. De Laet C, Kanis JA, Odén A, et al (2005). Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int*, 16:1330-1338.
 20. El Maghraoui A, Rezaqi A, El Mrahi S, et al (2014). Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women. *BMC Endocr Disord*, 14:93.
 21. von Muhlen D, Safii S, Jassal SK, et al (2007). Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. *Osteoporos Int*, 18:1337-1344.
 22. Shin CS, Choi HJ, Kim MJ, et al (2010). Prevalence and risk factors of osteoporosis in Korea: a community-based cohort study with lumbar spine and hip bone mineral density. *Bone*, 47:378-387.
 23. Manocha A, Srivastava LM, Bhargava S (2017). Lead as a risk factor for osteoporosis in postmenopausal women. *Indian J Clin Biochem*, 32:261-265.
 24. Jeon YJ, Kim JW, Park JS (2014). Factors associated with the treatment of osteoporosis in Korean postmenopausal women. *Women Health*, 54:48-60.
 25. Shin MS, Cho EH, Kim HY (2017). Longitudinal change in trabecular bone score during and after treatment of osteoporosis in postmenopausal Korean women. *J Bone Metab*, 24:117-124.
 26. Grundy SM, Cleeman JI, Daniels SR, et al (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 112:2735-2752.
 27. Aye M, Sazali M (2012). Waist circumference and BMI cut-off points to predict risk factors for metabolic syndrome among outpatients in a district hospital. *Singapore Med J*, 53:545-550.
 28. Sözen T, Özışık L, Başaran NÇ (2017). An overview and management of osteoporosis. *Eur J Rheumatol*, 4:46-56.
 29. Bridges MJ, Ruddick S (2011). Are metatarsal fractures indicative of osteoporosis in postmenopausal women? *Foot Ankle Spec*, 4:271-273.
 30. Cui LH, Shin MH, Chung EK, et al (2005). Association between bone mineral densities and serum lipid profiles of pre- and postmenopausal rural women in South Korea. *Osteoporos Int*, 16:1975-1981.
 31. Massé PG, Tranchant CC, Dosy J, et al (2005). Coexistence of osteoporosis and cardiovascular disease risk factors in apparently healthy, untreated postmenopausal women. *Int J Vitam Nutr Res*, 75:97-106.

32. Pekcan MK, Findik RB, Tokmak A, et al (2018). The relationship between breast density, bone mineral density, and metabolic syndrome among postmenopausal Turkish women. *J Clin Densitom*, 2018 Nov 8. pii:S1094-6950(18)30185-9. [Epub ahead of print].
33. Kim BJ, Ahn SH, Bae SJ, et al (2013). Association between metabolic syndrome and bone loss at various skeletal sites in postmenopausal women: a 3-year retrospective longitudinal study. *Osteoporos Int*, 24:2243-2252.
34. Zengin A, Prentice A, Ward KA (2015). Ethnic differences in bone health. *Front Endocrinol (Lausanne)*. 6:24.
35. El Maghraoui A, Koumba BA, Jroundi I, et al (2005). Epidemiology of hip fractures in 2002 in Rabat, Morocco. *Osteoporos Int*, 16:597-602.
36. Sadat-Ali M, Al-Habdan IM, Al-Mulhim FA, et al (2004). Bone mineral density among postmenopausal Saudi women. *Saudi Med J*, 25:1623-1625.